Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A. Kentepozidis N, et al. Among authors: koinis f. Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4. Clin Transl Oncol. 2017. PMID: 27492015 Clinical Trial.
Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).
Matikas A, Kentepozidis Ν, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulias V, Kotsakis A; HORG’s Lung Cancer Working Group. Matikas A, et al. Among authors: koinis f. Cancer Chemother Pharmacol. 2016 Aug;78(2):369-76. doi: 10.1007/s00280-016-3094-7. Epub 2016 Jun 22. Cancer Chemother Pharmacol. 2016. PMID: 27335027 Clinical Trial.
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, Mavroudis D, Georgoulias V. Kotsakis A, et al. Among authors: koinis f. Br J Cancer. 2016 Sep 27;115(7):784-8. doi: 10.1038/bjc.2016.281. Epub 2016 Sep 8. Br J Cancer. 2016. PMID: 27607471 Free PMC article. Clinical Trial.
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A. Koinis F, et al. Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16. Br J Cancer. 2017. PMID: 28510571 Free PMC article. Clinical Trial.
Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Messaritakis I, Nikolaou M, Koinis F, Politaki E, Koutsopoulos A, Lagoudaki E, Vetsika EK, Georgoulias V, Kotsakis A. Messaritakis I, et al. Among authors: koinis f. Lung Cancer. 2019 Sep;135:33-39. doi: 10.1016/j.lungcan.2019.06.025. Epub 2019 Jun 28. Lung Cancer. 2019. PMID: 31447000
Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V. Milaki G, et al. Among authors: koinis f. Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18. Cancer Chemother Pharmacol. 2017. PMID: 28523597
Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.
Messaritakis I, Politaki E, Koinis F, Stoltidis D, Apostolaki S, Plataki M, Dermitzaki EK, Georgoulias V, Kotsakis A. Messaritakis I, et al. Among authors: koinis f. Sci Rep. 2018 Feb 2;8(1):2238. doi: 10.1038/s41598-018-20502-1. Sci Rep. 2018. PMID: 29396560 Free PMC article. Clinical Trial.
45 results